Medthority· @Medthority · X·· 13 小时前评分70
正文 · 原文
#ESMO26
DeLLphi-305: Tarlatamab + durvalumab significantly improved OS vs durvalumab alone as 1LM therapy for ES-SCLC.
📊 Median OS: 21.1 vs 12.7 months
📉 Risk of death reduced by 58%
Presented by @sands_jacob
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
96 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Medthority · x.com